Brings Wealth of Value Creation Experience to BioTime
ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 31, 2016--
BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company
with a focus on pluripotent stem cell technologies, today announced that
the company has appointed Jim Knight as Senior Vice President, Head of
Corporate Development. He reports to Adi Mohanty, Co-Chief Executive
In his new role, Mr. Knight will oversee business development, portfolio
strategy and strategic marketing. He brings more than 20 years of
experience in creating portfolio value at publicly-traded companies
including, Questcor Pharmaceuticals, Inc. and Elan Pharmaceuticals.
“Jim is a highly-accomplished professional with an extensive skill set
and knowledge that is applicable immediately, as we have started
reporting encouraging early clinical data on our key programs,” said Mr.
Mohanty. “I’m confident that his track record of value creation,
particularly during his time at Questcor, where he helped drive
portfolio expansion that grew revenue from $150 million to more than $1
billion over a period of just four years, will assist us during this
exciting juncture and help us create value for our shareholders.”
Most recently, Mr. Knight was the Vice President of Portfolio Strategy
at Questcor from 2010 through 2014. Questcor was acquired by
Mallinckrodt Pharmaceuticals for $5.6 billion in that year, and Mr.
Knight stayed on for a transition and integration period through 2015.
Prior to Questcor, Mr. Knight was at Elan Pharmaceuticals from 2001 to
2008, where he led a global strategic marketing team, working closely
with collaborators at Biogen Inc. on the successful development and
commercialization of Tysabri, a monoclonal antibody. He started his
career in the research group at Biogen, before moving to sales and
market analysis roles. Mr. Knight has a BS in Biology from the
University of Massachusetts, Amherst and an MBA in High Technology from
“I am excited to join the BioTime team,” said Mr. Knight. “The company’s
proprietary pluripotent stem cells and HyStem delivery system have a
growing body of data that support significant potential to deliver on
revolutionary products. I feel confident that I can help accelerate the
development of these products internally as well through appropriate
BioTime, Inc. is a clinical-stage biotechnology company focused on
developing and commercializing novel therapies developed from what the
company believes to be the world’s premier collection of pluripotent
cell assets. The foundation of BioTime’s core therapeutic technology
platform is pluripotent cells that are capable of becoming any of the
cell types in the human body. Pluripotent cells have potential
application in many areas of medicine with large unmet patient needs,
including various age-related degenerative diseases and degenerative
conditions for which there presently are no cures. Unlike
pharmaceuticals that require a molecular target, therapeutic strategies
based on the use of pluripotent cells are generally aimed at
regenerating or replacing affected cells and tissues, and therefore may
have broader applicability than pharmaceutical products.
In addition to the development of therapeutics, BioTime’s research and
other activities have resulted, over time, in the creation of other
subsidiaries that address other non-therapeutic market opportunities
such as cancer diagnostics, drug development and cell research products,
and mobile health software applications.
BioTime common stock is traded on the NYSE MKT and TASE under the symbol
BTX. For more information, please visit www.biotimeinc.com
or connect with the company on Twitter,
To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list: http://news.biotimeinc.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161031005439/en/
Source: BioTime, Inc.
EVC Group, Inc.
Matt Haines, 917-733-9297
Gotham Communications, LLC
Bill Douglass, 646-504-0890